Leukotriene B-4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells
(2005) In Blood 105(3). p.1274-1279- Abstract
- Blosynthesis of leukotrienes (LTs) occurs in human myeloid cells and B lymphocytes. However, the function of leukotrienes in B lymphocytes is unclear. Here, we report that B-cell chronic lymphocytic leukemia (B-CLL) cells produce leukotriene B-4, and that specific leukotriene biosynthesis inhibitors counteracted CD40-dependent activation of B-CLL cells. Studies on the expression of the high-affinity receptor for LTB4 (BLT1) by flow cytometry analysis showed that the receptor was expressed, to a varying degree, in all investigated B-CLL clones. At a concentration of 100 nM, the drugs BWA4C (a specific 5-lipoxygenase inhibitor) and MK-886 (a specific 5-lipoxygenase activating protein inhibitor) markedly inhibited CD40-induced DNA synthesis... (More)
- Blosynthesis of leukotrienes (LTs) occurs in human myeloid cells and B lymphocytes. However, the function of leukotrienes in B lymphocytes is unclear. Here, we report that B-cell chronic lymphocytic leukemia (B-CLL) cells produce leukotriene B-4, and that specific leukotriene biosynthesis inhibitors counteracted CD40-dependent activation of B-CLL cells. Studies on the expression of the high-affinity receptor for LTB4 (BLT1) by flow cytometry analysis showed that the receptor was expressed, to a varying degree, in all investigated B-CLL clones. At a concentration of 100 nM, the drugs BWA4C (a specific 5-lipoxygenase inhibitor) and MK-886 (a specific 5-lipoxygenase activating protein inhibitor) markedly inhibited CD40-induced DNA synthesis (45% and 38%, respectively) and CD40-induced expression of CD23, CD54, and CD150. Addition of exogenous LTB4 (150 nM) almost completely reversed the effect of the inhibitors on DNA synthesis and antigen expression. Taken together, the results of the present study suggest that leukotriene biosynthesis inhibitors may have a therapeutic role in B-CLL. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/254962
- author
- Runarsson, G ; Liu, AQ ; Mahshid, Y ; Feltenmark, S ; Pettersson, Annika LU ; Klein, E ; Bjorkholm, M and Claesson, HE
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 105
- issue
- 3
- pages
- 1274 - 1279
- publisher
- American Society of Hematology
- external identifiers
-
- pmid:15454480
- wos:000226596700059
- scopus:12844258796
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2004-07-2546
- language
- English
- LU publication?
- yes
- id
- 2e01a9ca-ecc8-428f-9e35-57c7d7f4afc6 (old id 254962)
- date added to LUP
- 2016-04-01 12:07:54
- date last changed
- 2022-03-13 05:44:49
@article{2e01a9ca-ecc8-428f-9e35-57c7d7f4afc6, abstract = {{Blosynthesis of leukotrienes (LTs) occurs in human myeloid cells and B lymphocytes. However, the function of leukotrienes in B lymphocytes is unclear. Here, we report that B-cell chronic lymphocytic leukemia (B-CLL) cells produce leukotriene B-4, and that specific leukotriene biosynthesis inhibitors counteracted CD40-dependent activation of B-CLL cells. Studies on the expression of the high-affinity receptor for LTB4 (BLT1) by flow cytometry analysis showed that the receptor was expressed, to a varying degree, in all investigated B-CLL clones. At a concentration of 100 nM, the drugs BWA4C (a specific 5-lipoxygenase inhibitor) and MK-886 (a specific 5-lipoxygenase activating protein inhibitor) markedly inhibited CD40-induced DNA synthesis (45% and 38%, respectively) and CD40-induced expression of CD23, CD54, and CD150. Addition of exogenous LTB4 (150 nM) almost completely reversed the effect of the inhibitors on DNA synthesis and antigen expression. Taken together, the results of the present study suggest that leukotriene biosynthesis inhibitors may have a therapeutic role in B-CLL.}}, author = {{Runarsson, G and Liu, AQ and Mahshid, Y and Feltenmark, S and Pettersson, Annika and Klein, E and Bjorkholm, M and Claesson, HE}}, issn = {{1528-0020}}, language = {{eng}}, number = {{3}}, pages = {{1274--1279}}, publisher = {{American Society of Hematology}}, series = {{Blood}}, title = {{Leukotriene B-4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells}}, url = {{http://dx.doi.org/10.1182/blood-2004-07-2546}}, doi = {{10.1182/blood-2004-07-2546}}, volume = {{105}}, year = {{2005}}, }